Ensign Peak Advisors
BMY icon

Ensign Peak Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Ensign Peak Advisors’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$165M Sell
2,865,663
-135,558
-5% -$7.78M 0.27% 74
2026
Q1 		$182M Buy
3,001,221
+785,725
+35% +$45.8M 0.34% 63
2025
Q4 		$120M Sell
2,215,496
-178,303
-7% -$8.58M 0.21% 97
2025
Q3 		$108M Buy
2,393,799
+591,041
+33% +$27.6M 0.18% 114
2025
Q2 		$83.4M Sell
1,802,758
-411,285
-19% -$20.2M 0.14% 138
2025
Q1 		$135M Sell
2,214,043
-36,810
-2% -$2.15M 0.26% 81
2024
Q4 		$127M Sell
2,250,853
-87,187
-4% -$4.87M 0.23% 89
2024
Q3 		$121M Buy
2,338,040
+80,561
+4% +$3.78M 0.21% 95
2024
Q2 		$93.8M Sell
2,257,479
-42,230
-2% -$1.89M 0.17% 109
2024
Q1 		$125M Sell
2,299,709
-310,467
-12% -$15.8M 0.23% 93
2023
Q4 		$134M Sell
2,610,176
-892,343
-25% -$46.8M 0.27% 83
2023
Q3 		$203M Sell
3,502,519
-735,497
-17% -$45.1M 0.43% 54
2023
Q2 		$271M Sell
4,238,016
-251,159
-6% -$16.8M 0.55% 41
2023
Q1 		$311M Buy
4,489,175
+26,450
+0.6% +$1.87M 0.67% 33
2022
Q4 		$321M Buy
4,462,725
+92,901
+2% +$7M 0.72% 29
2022
Q3 		$311M Sell
4,369,824
-188,768
-4% -$13.7M 0.77% 27
2022
Q2 		$351M Buy
4,558,592
+636,926
+16% +$48.5M 0.83% 25
2022
Q1 		$286M Buy
3,921,666
+1,851,821
+89% +$124M 0.58% 39
2021
Q4 		$129M Sell
2,069,845
-473,538
-19% -$27.8M 0.25% 94
2021
Q3 		$150M Sell
2,543,383
-33,428
-1% -$2.2M 0.31% 84
2021
Q2 		$172M Sell
2,576,811
-157,469
-6% -$10.3M 0.35% 80
2021
Q1 		$173M Buy
2,734,280
+253,416
+10% +$15.8M 0.37% 73
2020
Q4 		$154M Buy
2,480,864
+903,931
+57% +$55.6M 0.35% 71
2020
Q3 		$95.1M Buy
1,576,933
+502,967
+47% +$30.3M 0.24% 85
2020
Q2 		$63.1M Buy
1,073,966
+73,774
+7% +$4.41M 0.17% 109
2020
Q1 		$55.8M Sell
1,000,192
-149,469
-13% -$9.14M 0.19% 99
2019
Q4 		$73.8M Buy
+1,149,661
New +$65.8M 0.19% 95

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ensign Peak Advisors's BMY Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Bristol-Myers Squibb (BMY) stake by 4.5% in Q2 2026, selling an estimated $7.78M and leaving 2,865,663 shares worth $165M. The position accounts for 0.27% of the portfolio, ranked #74.

Ensign Peak Advisors first reported a position in BMY in Q4 2019 and has held it in 27 quarters since. The position peaked at $351M in Q2 2022. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Ensign Peak Advisors held 2,865,663 shares of Bristol-Myers Squibb worth $165M as of Q2 2026.
  • Ensign Peak Advisors sold 135,558 Bristol-Myers Squibb shares in Q2 2026, an estimated $7.78M.
  • Bristol-Myers Squibb made up 0.27% of Ensign Peak Advisors's portfolio in Q2 2026, its #74 holding.
  • Ensign Peak Advisors first reported a position in Bristol-Myers Squibb in Q4 2019 and has held it in 27 quarters since.
  • Ensign Peak Advisors's Bristol-Myers Squibb position peaked at $351M in Q2 2022.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.